A Phase 3, Randomized, Open-label Study for Participants with Later-lines of Metastatic Colorectal Cancer by Bristol-Myers Squibb

Interventions: Experimental: Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC(BMS-986213), Specified dose on specified days)
Active Comparator: Arm B: Investigator’s Choice
Treatment with Regorafenib or TAS-102 (Specified dose on specified days)
Primary outcome(s): 1. Overall survival (OS) in randomized participants with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >- 1 [ Time Frame: Up to 5 years after last participant randomized ]
2. OS in all randomized participants [ Time Frame: Up to 5 years after last participant randomized ]
Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose